New combo therapy aims to shrink enlarged spleens in bone marrow cancer patients
NCT ID NCT07424950
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding bomedemstat to the standard drug momelotinib can help people with myelofibrosis, a type of bone marrow cancer. It is for patients whose spleen is still enlarged after 12 weeks on momelotinib alone. The main goal is to see if the combination reduces spleen size by at least 35% after 24 weeks of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Heart safety check for new myelofibrosis drug in healthy volunteers
- Targeted drug aims to stop blood cancer return after transplant
- Could a JAK inhibitor improve stem cell transplant success in myelofibrosis?
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug candidate targets Hard-to-Treat blood cancers